Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Huntington's Disease: early-phase trial registry

3 of 9 indexed Huntington's Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Huntington's Disease: 9 US clinical trials tracked, 3 recruiting.

Huntington's Disease is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 3 of these trials.

Enrollment posture brief

Registry condition huntingtons-disease

OPEN 3 | RECR 33% | LATE 0 | EARLY 4 | RANK #1916 | SPON 3

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Huntington's Disease (this)33%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Huntington's Disease

Huntington's Disease lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Huntington's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Huntington's Disease is recruiting below its size-band peers.

    3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Huntington's Disease research.

    Pfizer accounts for 3 of 9 trials (33.3%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Huntington's Disease enrolment sits around 75 participants.

    Median target enrolment is 75 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Huntington's Disease splits between interventional and observational designs.

    5 interventional and 4 observational studies make up this index (55.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 21

Open and recent trials

9 total, page 1 of 1

RECRUITING 35,000 participants

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

CHDI Foundation

NCT01574053

RECRUITING 2,500 participants

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

University College, London

NCT02855476

RECRUITING 400 participants

Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease

Peggy C Nopoulos

NCT01860339

ACTIVE NOT RECRUITING Phase 1 43 participants

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

UniQure Biopharma B.V.

NCT04120493

COMPLETED Phase 2 272 participants

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

Pfizer

NCT02197130

COMPLETED 75 participants

FuRST 2.0 Cognitive Pre-Testing

CHDI Foundation

NCT02881931

COMPLETED NA 24 participants

The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington's Disease

Anne Kloos

NCT01735981

COMPLETED Phase 1 20 participants

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

Pfizer

NCT00824590

COMPLETED Phase 1 14 participants

A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

Pfizer

NCT00827034

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Huntington's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Dimebon Drug
2 trials
hand-held video game Other
1 trials
Video game exercise using Dance Dance Revolution Other
1 trials
FuRST 2.0 Behavioral
1 trials
PF-02545920 Drug
1 trials
Imitation (sham) surgery Other
1 trials
intra-striatal rAAV5-miHTT Genetic
1 trials
Warfarin Drug
1 trials

US sites by state

Facility locations filed on Huntington's Disease trials. A trial with sites in several states counts in each.

Colorado 5 trials
California 4 trials
Texas 3 trials
Tennessee 3 trials
Ohio 3 trials
New York 3 trials
Florida 3 trials
Arizona 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Huntington's Disease page

9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Huntington's Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Pfizer sponsors the most Huntington's Disease trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Huntington's Disease condition card totals 9 registered trials; most-linked intervention Dimebon; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.